PhenoVista Biosciences was founded in 2014 by scientists from MIT and the University of California, San Diego (UCSD). The company is privately owned and headquartered in San Diego, California, operating as a 100% service-based CRO. It operates exclusively within the preclinical drug discovery space, with no clinical or manufacturing services in its portfolio.

PhenoVista’s core proposition is the development and execution of multiplexed, high-content imaging-based phenotypic cellular assays, used by biopharmaceutical clients to generate quantitative, functional, structural, and mechanistic data on drug candidates prior to clinical entry. The company serves clients of all sizes — from early-stage biotechs to large global pharmaceutical organisations — with over 200 companies across the US, UK, Europe, and Asia having engaged PhenoVista since its founding. Key metrics reported by the company include over 500 custom studies completed, more than 1.2 million wells imaged, and 4 billion cells stained, with 90% of top pharmaceutical companies cited as clients and an 80% repeat customer rate.

The company’s scientific team is predominantly PhD-level and draws on expertise spanning biomedical engineering, neurobiology, oncology, and data science. In 2024, PhenoVista became affiliated with InSphero, a Swiss 3D cell biology company, as reflected in its co-branded identity. The company’s services are available to purchase directly, via Scientist.com, and via Science Exchange.

Key Products and Services

Service Offerings

• Custom Assays — fully bespoke assay design, development, execution, and analysis tailored to specific biological questions; no protocol transfer required; spans initial assay development through to data mining and optional outbound technology transfer back to the client
• Ready-2-Go (R2G) Assays — predefined, off-the-shelf assay panels across a range of disease and therapeutic areas, with standardised cell models, fluorescent stains, and timepoints; client selects compounds
• Cell Painting and Morphological Screening — high-content, morphology-based screening using U-2 OS or A549 cell lines to compare compound effects against reference compounds using the standardised Cell Painting protocol; supports mechanism-of-action profiling and compound library screening
• Imaging and Analysis — an image-only service in which clients ship fixed and stained cell plates to PhenoVista for high-content imaging, quantitative analysis, and data reporting

Engagement Models

• Consultation — scientific advisory, complex re-analysis of existing datasets; flexible and suitable for single or ongoing engagements
• Project-Based — modular project commissioning; suitable for pilot studies and exploratory programmes across the full range of research areas
• FTE (Full-Time Equivalent) — dedicated resource allocation with priority access and a named scientific point of contact; maximum flexibility for ongoing programmes

Research Areas

• Fibrosis — fibrotic inhibition and induction assays; assessment of candidate compound effects on fibroblast activation, collagen deposition, and related endpoints
• Neurobiology — neuronal health and neurotoxicity assay suites using human iPSC-derived neurons and glia; CNS-relevant cell models including 3D neurosphere formats
• Oncology and Immuno-oncology — tumour biology assays using patient-derived samples, cancer organoids, and CAR-T cell cytotoxicity models; biologically relevant systems for solid and haematological malignancy programmes
• Cell and Gene Therapy — assay development supporting cell and gene therapy candidates, including delivery assessment and therapeutic efficacy readouts

Technical Capabilities

• Cell models: immortalised cell lines, primary cells, iPSC-derived cells, patient-derived samples; formats include 2D, 3D (spheroids, organoids, 3D bioprinted co-cultures), mono-culture, and co-culture
• Therapeutic modalities assessed: small molecules, monoclonal antibodies, antibody-drug conjugates, biologics, peptides, and therapeutic siRNAs
• Assay readouts: cytotoxicity, target identification and validation, therapeutic efficacy, mechanism-of-action determination, and therapeutic delivery
• Imaging platforms: automated confocal microscopy; scalable liquid handling; proprietary in-house informatics for image analysis and data mining; live-cell and multi-timepoint imaging workflows

PhenoVista occupies a well-defined niche as a specialist imaging CRO at the early preclinical end of the drug development continuum. Its focus on high-content imaging-based phenotypic assays — rather than the broader biochemical or in vivo service portfolios offered by larger preclinical CROs — allows it to offer a depth of imaging expertise and cell biology specificity that generalist providers typically cannot match. The company’s use of physiologically relevant cell models, including iPSC-derived cells, patient-derived samples, and complex 3D culture systems, positions it alongside sponsors who require biologically meaningful preclinical data rather than simple screening throughput. Its affiliation with InSphero extends this positioning further into the 3D cell biology and organ-on-a-chip space. With over a decade of operational history, a high repeat-client rate, and a client base that includes the majority of top global pharmaceutical companies, PhenoVista’s track record supports its standing as a credible specialist partner for early-stage drug discovery programmes across oncology, neuroscience, fibrosis, and cell and gene therapy.